Zoledronic Acid for the Prevention of Bone Loss Post-bone Marrow Transplantation for Thalassemia Major Patients
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is prospective randomized, double blind study designed to evaluate the use of zoledronic
acid in the prevention prevention of bone loss post allogenic BMT done for beta-thalassemia
major patients.